<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9315">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05700643</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00008275</org_study_id>
    <nct_id>NCT05700643</nct_id>
  </id_info>
  <brief_title>Montmorency Cherry Supplementation, Sleep, and Inflammation</brief_title>
  <official_title>Effects of Montmorency Cherry Supplementation on Sleep and Inflammatory Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michigan State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cherry Marketing Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Michigan State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the effects of Montmorency cherry supplementation on sleep outcomes and&#xD;
      inflammatory biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 18, 2023</start_date>
  <completion_date type="Anticipated">January 17, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total sleep time</measure>
    <time_frame>Through study completion, two weeks for each arm</time_frame>
    <description>sleep duration in hours and minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sleep quality</measure>
    <time_frame>Through study completion, two weeks for each arm</time_frame>
    <description>Pittsburgh Sleep Quality Index scores, scores range from 0-21, higher scores indicate worse outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insomnia symptoms</measure>
    <time_frame>Through study completion, two weeks for each arm</time_frame>
    <description>Insomnia Severity Index scores, scores range from 0-28, higher scores indicate worse outcomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive protein</measure>
    <time_frame>Through study completion, two weeks for each arm</time_frame>
    <description>blood work</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-6</measure>
    <time_frame>Through study completion, two weeks for each arm</time_frame>
    <description>blood work</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-8</measure>
    <time_frame>Through study completion, two weeks for each arm</time_frame>
    <description>blood work</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-17</measure>
    <time_frame>Through study completion, two weeks for each arm</time_frame>
    <description>blood work</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tumor necrosis factor-alpha</measure>
    <time_frame>Through study completion, two weeks for each arm</time_frame>
    <description>blood work</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anthropometrics</measure>
    <time_frame>Through study completion, two weeks for each arm</time_frame>
    <description>Percent body fat</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Insomnia Chronic</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg cherry supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Montmorency cherry supplement</intervention_name>
    <description>Montmorency cherry supplement</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  body mass index (BMI) of â‰¥ 25.0 kg/m2;&#xD;
&#xD;
          -  sleep issues as identified by a global score of 5 or greater on the Pittsburgh Sleep&#xD;
             Quality Index (PSQI) and/or a score 8 or higher on the Insomnia Severity Index (ISI);&#xD;
&#xD;
          -  ability to adhere to a diet low in antioxidants during the study period; and&#xD;
&#xD;
          -  willingness to wear a Fitbit for the duration of the study and to wear the Zmachine on&#xD;
             selected nights.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unwilling or unable to stop the use of sleep medication&#xD;
&#xD;
          -  unable to attend laboratory visits on the East Lansing, Michigan campus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robin Tucker, PhD</last_name>
    <phone>517-353-3408</phone>
    <email>tucker98@msu.edu</email>
  </overall_contact>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 7, 2022</study_first_submitted>
  <study_first_submitted_qc>January 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>January 17, 2023</last_update_submitted>
  <last_update_submitted_qc>January 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Michigan State University</investigator_affiliation>
    <investigator_full_name>Robin Tucker</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Aggregate data available upon request upon completion of analysis.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

